Restart Life Closes Over-Subscribed Second Tranche Financing

Rhea-AI Summary

Restart Life Sciences (OTC: NMLSF) closed an over-subscribed second tranche of a non-brokered private placement on December 18, 2025, raising gross proceeds of CDN$630,000 in the tranche and CDN$1,130,000 in total across two tranches.

The company issued 6,300,000 units at CDN$0.10 per unit; each unit includes one common share and one transferable warrant exercisable for one year at CDN$0.10. The company also issued 132,000 non-transferable finder warrants exercisable for one year at CDN$0.10. Proceeds are earmarked for health food trials, potential acquisitions, and general working capital. Securities are subject to a four-month-and-one-day hold expiring April 18, 2026.

Positive

• Second tranche raised CDN$630,000 on December 18, 2025
• Total financing reached CDN$1,130,000 across two tranches
• Issued 6,300,000 units at CDN$0.10 per unit
• Proceeds allocated to health food trials, acquisitions, and working capital

Negative

• Potential dilution from 6,432,000 warrants and finder warrants exercisable at CDN$0.10
• Warrants expire in one year, creating short-term exercise uncertainty
• All securities subject to a hold until April 18, 2026, limiting immediate liquidity

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025 and December 5, 2025, the Company has closed the over-subscribed second tranche of its non-brokered private placement for total gross proceeds of CDN$630,000 (the "Placement"). As announced on November 12, 2025, the company intended to raise a total of up to CDN$1,000,000 however due to overwhelming interest in the company's objectives, the company has raised a total of CDN$1,130,000 in two tranches.

Pursuant to the Second Tranche of the Private Placement, the Company has allotted and issued 6,300,000 units (the "Units") at a price of CDN$0.10 per Unit. Each Unit consists of one common share and one transferable common share purchase warrant (each, a "Warrant"). Each Warrant entitles the holder to purchase one additional common share for a period of one (1) year at a price of CDN$0.10 per common share.

In connection with the Placement, the Company issued 132,000 non-transferable finder warrants (each, a "Finder Warrant") to certain eligible arm's-length finders who introduced subscribers to the Placement. Each Finder Warrant entitles the holder to purchase one common share for a period of one (1) year at a price of CDN$0.10 per common share.

The Company intends to use the proceeds from the Offering towards health food trials, potential acquisitions, and general working capital. All securities issued under the Placement are subject to a hold period of four months and one day expiring on April 18, 2026.

About Restart Life Sciences Corp.
Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.

On behalf of the Board of Directors
Steve Loutskou
Chief Executive Officer, Restart Life Sciences Corp.
Tel: +1 (778) 819-0244
Email: hello@restartlife.co

Forward-Looking Statements
This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart Life Sciences' actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278447

FAQ

How much did Restart Life Sciences (NMLSF) raise in the December 18, 2025 tranche?

The second tranche raised CDN$630,000, bringing total proceeds to CDN$1,130,000.

What were the unit and warrant terms for Restart Life Sciences (NMLSF) private placement?

The company issued units at CDN$0.10 each; each unit includes one share and one warrant exercisable for one year at CDN$0.10.

How many units and finder warrants did Restart Life Sciences (NMLSF) issue on December 18, 2025?

The company issued 6,300,000 units and 132,000 non-transferable finder warrants.

When do securities from Restart Life Sciences (NMLSF) placement come out of hold?

All securities are subject to a four-month-and-one-day hold, expiring on April 18, 2026.

What will Restart Life Sciences (NMLSF) use the proceeds for after the December 2025 placement?

Proceeds are intended for health food trials, potential acquisitions, and general working capital.